TAPUR Trial Leverages Genomic Testing for Precision Medicine
In this video, Dr. Edward Kim provides details on the TAPUR trial, which uses broad genomic test results to aid in precision medicine for cancer patients.
Edward Kim, MD, FACP, of the Levine Cancer Institute, Carolinas Healthcare System, in Charlotte, North Carolina, discusses aspects of the ASCO-led TAPUR trial, which utilizes genomic testing to identify markers that can be targeted by specific drugs, giving certain patients access to drugs they wouldn't otherwise be able to access for their disease.
We spoke with Dr. Kim at the 2017 ASCO Annual Meeting because his institution is one of the lead sites participating in the TAPUR trial.
Nurse-Led Program May Increase Germline Testing in Black Veterans With Cancer
June 1st 2023The association between use of a telegenetics service and lower likelihood of germline testing was statistically significant among black veterans with cancer, according to a recent retrospective cohort study.
New NSCLC Treatment Options Needed to Successfully Target Multiple Gene Changes
November 24th 2017Researchers analyzed samples from 1,122 patients with advanced-stage NSCLC and discovered that 92.9% of tumors from harbored multiple changes in cancer-related genes in addition to the EGFR driver mutation.
